Texas AG Sues Tylenol Over Autism
Ken Paxton, the Attorney General of Texas, has filed a lawsuit against Johnson & Johnson and its spinoff Kenvue (which now markets Tylenol) in a Texas state court alleging that the companies deceptively marketed acetaminophen (the active ingredient in Tylenol) to pregnant women despite purported risks to unborn children — including increased risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).
The lawsuit claims that Johnson & Johnson and Kenvue “willfully ignored and attempted to silence the science” linking prenatal exposure to acetaminophen with neurodevelopmental disorders, even while marketing Tylenol as the safe choice for pregnant individuals. The filing also asserts that Johnson & Johnson attempted to evade liability by transferring its consumer-health business and associated liabilities to Kenvue in order to shield itself from future lawsuits.
Paxton’s suit focuses on two major legal theories: (1) violations of the Texas Deceptive Trade Practices-Consumer Protection Act (DTPA), alleging false or misleading marketing of Tylenol; and (2) violations of the Texas Uniform Fraudulent Transfer Act (UFTA), alleging that Johnson & Johnson transferred liabilities to Kenvue to avoid responsibility.
From a scientific perspective, the underlying claims are controversial. Some observational studies have suggested a possible association between acetaminophen use in pregnancy and autism or ADHD, but leading medical organizations and the U.S. Food & Drug Administration (FDA) emphasize that a causal relationship has not been established.
Kenvue has responded by stating that acetaminophen remains the safest over-the-counter pain-and-fever option for pregnant individuals when used as directed, and has called the allegations “baseless” and scientifically unsupported.
The lawsuit is the first of its kind by a state government alleging that Tylenol’s marketing to pregnant women was deceptive in light of alleged autism/ADHD risk. It arrives amid increasing public attention to potential neurodevelopmental risks and heightened scrutiny of pharmaceutical marketing practices.
Why It Matters
-
Consumer and maternal-health implications — The case raises major concerns about the safety of a common over-the-counter medication used by pregnant individuals, which if proven, could change guidance and usage.
-
Pharmaceutical-marketing accountability — It places Big Pharma’s marketing practices under heightened scrutiny, particularly how companies advise pregnant consumers and manage evidence of potential risks.
-
Emerging litigation frontier — This is a novel kind of state-level lawsuit linking acetaminophen to autism/ADHD, and could open the door to broader litigation and regulatory change if successful.
-
Science vs. legal standard tension — The case sits at the intersection of unsettled science (correlation vs. causation) and legal liability, highlighting how regulatory and legal frameworks grapple with medical uncertainty.
-
Political and public-trust dimensions — The lawsuit aligns with political-health discourse (including statements by former President Donald Trump and Health Secretary Robert F. Kennedy Jr.) and could influence public perceptions of pharmaceutical safety and state-level oversight of health claims.
Key Legal Outcome
-
Lawsuit filed by Texas AG — Ken Paxton’s office has formally filed suit in a Texas state court against Johnson & Johnson and Kenvue alleging deceptive marketing tied to Tylenol use in pregnancy.
-
Claims under state consumer-protection law — The complaint alleges violations of the Texas Deceptive Trade Practices-Consumer Protection Act for marketing Tylenol as safe for pregnant women despite alleged risks.
-
Fraudulent-transfer allegation — The suit asserts that Johnson & Johnson transferred liabilities from Tylenol risks to Kenvue to avoid legal responsibility, violating the Texas Uniform Fraudulent Transfer Act.
-
Relief sought includes injunctive and monetary remedies — The state seeks to ban future deceptive marketing, destroy marketing materials that mischaracterize safety, and impose civil penalties for each violation.
-
Scientific causation not yet established — While the legal claims rely on alleged risk, medical consensus remains that no direct causal link has been proved between acetaminophen in pregnancy and autism/ADHD, which may become a key point of defense.
